Celldex Therapeutics (CLDX) Other Non-Current Liabilities (2010 - 2026)

Celldex Therapeutics' Other Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 22.41% year-over-year to $3.1 million in Q1 2026; TTM through Mar 2026 was $3.1 million, a 22.41% increase from a year earlier, with the FY2025 full-year figure at $4.0 million, up 16.41% from the prior year.
• Other Non-Current Liabilities fell to $3.1 million in Q1 2026 per CLDX's latest filing, from $4.0 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $10.5 million in Q1 2022 and bottomed at $2.5 million in Q1 2025.
• The 5-year median for Other Non-Current Liabilities is $4.0 million (2025), against an average of $4.3 million.
• Across the five-year window, Other Non-Current Liabilities soared 71.14% in 2022 and plunged 58.22% in 2023, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $5.3 million in 2022, then retreated by 17.44% to $4.4 million in 2023, then declined by 21.12% to $3.5 million in 2024, then grew by 16.41% to $4.0 million in 2025, then dropped by 23.0% to $3.1 million in 2026.
• Per Business Quant, the three latest CLDX Other Non-Current Liabilities figures stand at $3.1 million (Q1 2026), $4.0 million (Q4 2025), and $2.5 million (Q3 2025).